Genmab — Januar 2020
-
-
-
Fra Q4 2018: So compared to the total license agreement, $1.015 billion, that would mean that we've got $444 million to come still within that program. As I said originally, those are split between multiple myeloma milesto
nes, nonmultiple myeloma milestones and sales hurdle milestones. -
Så er milepælsagen klar. IR har svaret: "Der er ikke flere større kommercielle milepælsbetalinger efter de USD 3bn er opnået.
De resterende milepælsbetalinger relaterer sig til andre ting såsom godkendelser i andre indikationer, udviklingsmilepæle osv." -
Første kinesiske bioteknotering i USA i to år rammer ved siden af
Det kinesiske biotekselskab I-mab, som blandt andet udvikler en konkurrent til Darzalex, har rejst enorme summer igennem de seneste år, men på den amerikanske børs, fik ledelsen ikke, hvad den havde sigtet efter.
(medwatch.dk)
-
Sydbank om regnskabssæsonen: Skuffelser kan koste dyrt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind